women with POI than in the reference data obtained from 1,927 subjects, whereas it was similar between the 102 women with POI and 102 control women. Jaroudi et al. [1994] identified no significant difference in the frequency of HLA loci between 37 women with POI and 100 control women. In these studies, however, HLA typing was performed by classic serological methods rather than refined genotyping methods, and haplotype analysis was not performed, while the Bonferroni correction was utilized to cope with multiple comparisons. Thus, while a possible association of POI with DR3 and/or DR4 may be suggested, this matter awaits further investigations. In this context, it may be worth pointing out that the present study failed to identify a positive association between POI and DR3 (DRB1*03) or DR4 (DRB1*04) (online suppl. table 1), although this may primarily be due to the ethnic difference, as has been shown in T1DM [Thomson et al., 2007].

Several points should be made with respect to the present study. First, the specific HLA haplotype accounts for only a minor portion (4.82%) of haplotypes identified in women with POI. Second, affected women may have some unidentified pathologic cause(s) for POI, such as mutations of hitherto unknown causative genes. Third, there may be some hidden polygenic and environmental differences between women with POI and the control subjects. Finally, it remains to be determined whether similar results can be reproduced in other studies. These matters imply that the etiologies of POI still remain elusive and await further investigations in most women with POI.

Despite the above caveats, the present study provides a useful clue to clarify the underlying factors for the development of POI. In summary, we propose that a specific HLA haplotype (A*24:02-C*03:03-B*35:01) constitutes a susceptibility factor for apparently isolated POI in Japanese women.

Acknowledgements

We would like to thank Professor Naoyuki Kamatani and Dr. Shigeo Kamitsuji, Department of Statistical Genetics, StaGen Co., Ltd., for their critical support in the genetic statistical analysis. This study was supported by Grant-in-Aid for Scientific Research on Innovative Areas from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) [22132004 to T.O.]; by Grants for Research on Intractable Diseases [H22-098 to T.O.]; by Grants for Health Research on Children, Youth and Families from the Ministry of Health, Labor and Welfare [H21-005 to T.O.]; and by Grant of National Center for Child Health and Development [20C-2 to T.O.].

References

Anasti JN, Adams S, Kimzey LM, Defensor RA, Zachary AA, Nelson LM: Karyotypically normal spontaneous premature ovarian failure: evaluation of association with the class II major histocompatibility complex. J Clin Endocrinol Metab 78:722–723 (1994).

Bakalov VK, Vanderhoof VH, Bondy CA, Nelson LM: Adrenal antibodies detect asymptomatic auto-immune adrenal insufficiency in young women with spontaneous premature ovarian failure. Hum Reprod 17:2096–2100 (2002).

Belvisi L, Bombelli F, Sironi L, Doldi N: Organ-specific autoimmunity in patients with premature ovarian failure. J Endocrinol Invest 16:886–892 (1993).

Betterle C, Rossi A, Dalla-Pria S, Artifoni A, Pedini B, et al: Premature ovarian failure: autoimmunity and natural history. Clin Endocrinol 39:35–43 (1993).

Cohen J: Statistical Power Analysis for the Behavioral Sciences, 2nd ed. (Lawrence Erlbaum Associates, New Jersey 1988).

Cronister A, Schreiner R, Wittenberger M, Amiri K, Harris K, Hagerman RJ: Heterozygous fragile X female: historical, physical, cognitive, and cytogenetic features. Am J Med Genet 38:269–274 (1991).

Di Pasquale E, Beck-Peccoz P, Persani L: Hypergonadotropic ovarian failure associated with an inherited mutation of human bone morphogenetic protein-15 *(BMP15)* gene. Am J Hum Genet 75:106–111 (2004).

Di Prospero F, Luzi S, Iacopini Z: Cigarette smoking damages women's reproductive life. Reprod Biomed Online 8:246–247 (2004).

Excoffier L, Slatkin M: Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 12: 921–927 (1995).

Howell S, Shalet S: Gonadal damage from chemotherapy and radiotherapy. Endocrinol Metab Clin North Am 27:927–943 (1998).

Ishizuka B, Kudo R, Amemiya A, Yamada H, Matsuda T, Ogata T: Anti-nuclear antibodies in patients with premature ovarian failure. Hum Reprod 14:70–75 (1999).

Jaroudi KA, Arora M, Sheth KV, Sieck UV, Willemsen WN: Human leukocyte antigen typing and associated abnormalities in premature ovarian failure. Hum Reprod 9:2006–2009 (1994).

Kalantaridou SN, Davis SR, Nelson LM: Premature ovarian failure. Endocrinol Metab Clin North Am 27:989–1006 (1998).

Kauffman RP, Castracane VD: Premature ovarian failure associated with autoimmune polyglandular syndrome: pathophysiological mechanisms and future fertility. J Womens Health (Larchmt) 12:513–520 (2003).

Kitamura Y, Moriguchi M, Kaneko H, Morisaki H, Morisaki T, et al: Determination of probability distribution of diplotype configuration (diplotype distribution) for each subject from genotypic data using the EM algorithm. Ann Hum Genet 66:183–193 (2002).

Kovanci E, Rohozinski J, Simpson JL, Heard MJ, Bishop CE, Carson SA: Growth differentiating factor-9 mutations may be associated with premature ovarian failure. Fertil Steril 87:143–146 (2007).

Laml T, Schulz-Lobmeyr I, Obruca A, Huber JC, Hartmann BW: Premature ovarian failure: etiology and prospects. Gynecol Endocrinol 14:292–302 (2000).

Lourenço D, Brauner R, Lin L, De Perdigo A, Weryha G, et al: Mutations in *NR5A1* associated with ovarian insufficiency. N Engl J Med 360:1200–1210 (2009).

Moncayo-Naveda H, Moncayo R, Benz R, Wolf A, Lauritzen C: Organ-specific antibodies against ovary in patients with systemic lupus erythematosus. Am J Obstet Gynecol 160: 1227–1229 (1989).
Morrison JC, Givens JR, Wiser WL, Fish SA: Mumps oophoritis: a cause of premature menopause. Fertil Steril 26:655–659 (1975).
Qin Y, Zhao H, Kovanci E, Simpson JL, Chen ZJ, Rajkovic A: Analysis of *LHX8* mutation in premature ovarian failure. Fertil Steril 89: 1012–1014 (2008).
Qin Y, Shi Y, Zhao Y, Carson SA, Simpson JL, Chen ZJ: Mutation analysis of *NOBOX* homeodomain in Chinese women with premature ovarian failure. Fertil Steril 91 (Suppl):1507–1509 (2009).
Qu HQ, Polychronakos C: The effect of the MHC locus on autoantibodies in type 1 diabetes. J Med Genet 46:469–471 (2009).
Ryan MM, Jones HR Jr: Myasthenia gravis and premature ovarian failure. Muscle Nerve 30: 231–233 (2004).
Shaffer JP: Multiple hypothesis testing. Annu Rev Psychol 46:561–584 (1995).
Sharara FI, Seifer DB, Flaws JA: Environmental toxicants and female reproduction. Fertil Steril 70:613–622 (1998).
Thomson G, Valdes AM, Noble JA, Kockum I, Grote MN, et al: Relative predispositional effects of HLA class II DRB1-DQB1 haplotypes and genotypes on type 1 diabetes: a meta-analysis. Tissue Antigens 70:110–127 (2007).
Todd JA, Acha-Orbea H, Bell JI, Chao N, Fronek Z, et al: A molecular basis for MHC class II-associated autoimmunity. Science 240:1003–1009 (1988).
Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N: Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 96:434–442 (2004).
Walfish PG, Gottesman IS, Shewchuk AB, Bain J, Hawe BS, Farid NR: Association of premature ovarian failure with HLA antigens. Tissue Antigens 21:168–169 (1983).

Aromatase Excess Syndrome: Identification of Cryptic Duplications and Deletions Leading to Gain of Function of *CYP19A1* and Assessment of Phenotypic Determinants

Maki Fukami, Makio Shozu, Shun Soneda, Fumiko Kato, Akemi Inagaki, Hiroshi Takagi, Keiichi Hanaki, Susumu Kanzaki, Kenji Ohyama, Tomoaki Sano, Toshinori Nishigaki, Susumu Yokoya, Gerhard Binder, Reiko Horikawa, and Tsutomu Ogata

Department of Molecular Endocrinology (M.F., S.S., F.K., T.O.), National Research Institute for Child Health and Development, Tokyo 157-8535, Japan; Department of Reproductive Medicine (M.S.), Graduate School of Medicine, Chiba University, Chiba 206-8670, Japan; Department of Diabetes and Endocrinology (A.I., H.T.), Nagoya Second Red Cross Hospital Nagoya 466-8650, Japan; Department of Women's and Children's Family Nursing (K.H.) and Division of Pediatrics and Perinatology (S.K.), Tottori University, Yonago 683-8503, Japan; Department of Pediatrics (K.O., T.S.), Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Chuo 408-3898, Japan; Department of Pediatrics (T.N.), Osaka Police Hospital, Osaka 543-0035, Japan; Department of Medical Subspecialties (S.Y., R.H.), National Medical Center for Children and Mothers, Tokyo 157-8535, Japan; and Pediatric Endocrinology Section (G.B.), University Children's Hospital, Tuebingen 72076, Germany

Context: Aromatase excess syndrome (AEXS) is a rare autosomal dominant disorder characterized by gynecomastia. Although cryptic inversions leading to abnormal fusions between *CYP19A1* encoding aromatase and its neighboring genes have been identified in a few patients, the molecular basis remains largely unknown.

Objective: The objective of the study was to examine the genetic causes and phenotypic determinants in AEXS.

Patients: Eighteen affected males from six families participated in the study.

Results: We identified three types of heterozygous genomic rearrangements, *i.e.* a 79,156-bp tandem duplication involving seven of 11 noncoding *CYP19A1* exons 1, a 211,631-bp deletion involving exons 2–43 of *DMXL2* and exons 5–10 of *GLDN*, and a 165,901-bp deletion involving exons 2–43 of *DMXL2*. The duplicated exon 1 functioned as transcription start sites, and the two types of deletions produced the same chimeric mRNA consisting of *DMXL2* exon 1 and *CYP19A1* coding exons. The *DMXL2* exon 1 harbored a translation start codon, and the *DMXL2/CYP19A1* chimeric mRNA was identified in only 2–5% of *CYP19A1*-positive transcripts. This was in contrast to the inversion-mediated chimeric mRNA that had no coding sequence on the fused exon 1 and accounted for greater than 80% of *CYP19A1*-positive transcripts. *CYP19A1* was expressed in a limited number of tissues, whereas its neighboring genes involved in the chimeric mRNA formation were expressed widely.

Conclusions: This study provides novel mechanisms leading to gain of function of *CYP19A1*. Furthermore, it appears that clinical severity of AEXS is primarily determined by the tissue expression pattern of relevant genes and by the structural property of promoter-associated exons of chimeric mRNA. (***J Clin Endocrinol Metab* 96: E1035–E1043, 2011**)

ISSN Print 0021-972X ISSN Online 1945-7197
Printed in U.S.A.

doi: 10.1210/jc.2011-0145 Received January 18, 2011. Accepted March 22, 2011.
First Published Online April 6, 2011

Abbreviations: AEXS, Aromatase excess syndrome; CGH, comparative genomic hybridization; E_2, estradiol; FISH, fluorescence *in situ* hybridization; hCG, human chorionic gonadotropin; LCL, lymphoblastoid cell line; NMD, nonsense-mediated mRNA decay; RACE, rapid amplification of cDNA ends; SF, skin fibroblast; T, testosterone.

Aromatase is a cytochrome P450 enzyme that plays a crucial role in the estrogen biosynthesis (1). It catalyzes the conversion of Δ4-androstendione into estrone and that of testosterone (T) into estradiol (E_2) in the placenta and ovary as well as in other tissues such as the fat, skin, bone, and brain (1). It is encoded by *CYP19A1* consisting of at least 11 noncoding exons 1 and nine coding exons 2–10 (Supplemental Fig. 1, published on The Endocrine Society's Journals Online web site at http://jcem.endojournals.org) (2, 3). Each exon 1 is accompanied by a tissue-specific promoter and is spliced alternatively onto a common splice acceptor site at exon 2, although some transcripts are known to contain two of the exons 1, probably due to a splice error (2, 4). Of the 11 exons 1, exon I.4 appears to play a critical role in the regulation of estrogen biosynthesis in males because this exon contains a major promoter for extragonadal tissues including the skin and fat (2).

Excessive *CYP19A1* expression causes a rare autosomal dominant disorder known as aromatase excess syndrome (AEXS) (5–8). AEXS is characterized by pre- or peripubertal onset gynecomastia, advanced bone age from childhood to the pubertal period, and short adult height in affected males (5–8). Affected females may show several clinical features such as macromastia, precocious puberty, irregular menses, and short adult height (6–8). In this regard, previous studies have identified four heterozygous cryptic inversions around *CYP19A1* in patients with AEXS (5, 8). Each inversion results in the formation of a chimeric gene consisting of a noncoding exon(s) of a neighboring gene (*CGNL1*, *MAPK6*, *TMOD3*, or *TLN2*) and coding exons of *CYP19A1*. Because this condition is predicted to cause aberrant *CYP19A1* expression in tissues in which each neighboring gene is expressed, such inversions have been regarded to be responsible for AEXS (5, 8).

However, such inversions have been revealed only in a few patients with AEXS, and, despite extensive studies, no other underlying genetic mechanisms have been identified to date (6, 8–10). Here we report novel genomic rearrangements in AEXS and discuss primary phenotypic determining factors in AEXS.

Patients and Methods

Patients

This study was approved by the Institutional Review Board Committee at the National Center for Child Health and Development and was performed after obtaining informed consent. We examined 18 male patients aged 8–69 yr (cases 1–18) from six unrelated families A-F (Fig. 1A). The probands were ascertained by bilateral gynecomastia (Fig. 1B) and the remaining 12 males by familial studies. Ten other males allegedly had gynecomastia. There were four obligatory carrier females.

Phenotypic assessment showed pre- or peripubertal onset gynecomastia in all cases, small testes and fairly preserved masculinization in most cases, obvious or relative tall stature in childhood and grossly normal or relative short stature in adulthood, and age-appropriate or mildly advanced bone ages (Table 1) (for detailed actual data, see Supplemental Table 1). Such clinical features, especially gynecomastia, tended to be milder in cases 1–4 from families A and B than in the remaining cases from families C-F. Fertility or spermatogenesis was preserved in all adult cases (≥20 yr). In addition, the obligatory carrier females from families B and D had apparently normal phenotype, and such females from families E and F exhibited early menarche (9.0 yr) and short adult stature (−2.8 SD), respectively.

Blood endocrine studies revealed that LH values were grossly normal at the baseline and variably responded to GnRH stimulation, whereas FSH values were low at the baseline and responded poorly to GnRH stimulation, even after preceding GnRH priming (Table 1) (for detailed actual data, see Supplemental Table 1) (see also Fig. 1C for the cases aged ≥15 yr). Δ^4-Androstendione, T, and dihydrotestosterone values were low or normal. A human chorionic gonadotropin (hCG) test indicated relatively low but normal T responses in five young cases. In most cases, estrone values were elevated, E_2 values were normal or elevated, and E_2/T ratios were elevated. These endocrine data were grossly similar among cases 1–18.

Aromatase inhibitor (anastrozole, 1 mg/d) was effective in all the four cases treated (Supplemental Table 1) (see also Fig. 1C for cases aged ≥15 yr). Gynecomastia was mitigated within 6 months of treatment, and endocrine data were ameliorated within 1 month of treatment.

Primers

Primers used in this study are shown in Supplemental Table 2.

CYP19A1 mRNA levels and aromatase activities

We analyzed relative mRNA levels of *CYP19A1* and catalytic activities of aromatase in skin fibroblasts (SF) and lymphoblastoid cell lines (LCL). mRNA were extracted by a standard method and were subjected to RT-PCR using a high capacity RNA-to-cDNA kit (Life Technologies, Carlsbad, CA). A relative amount of *CYP19A1* mRNA against *B2M* was determined by the real-time PCR method using the Taqman gene expression assay on ABI PRISM 7500fast (Life Technologies) (assay no. Hs00903411_m1 for *CYP19A1* and Hs99999907_m1 for *B2M*). PCR was performed in triplicate. Aromatase activity was determined by a tritium incorporation assay (11). In brief, the samples were incubated with androstenedione-2-^{3}H for 2 h, and ^3H_2O in the supernatant of the culture media was measured with a scintillation counter LSC-5100 (Aloka, Tokyo, Japan).

Sequence analysis of *CYP19A1*

Leukocyte or SF genomic DNA samples from the six probands and additional four male patients (Fig. 1A) were PCR amplified for the coding exons 2–10 and their flanking splice sites of *CYP19A1*. Subsequently the PCR products were subjected to direct sequencing from both directions on CEQ 8000 autosequencer (Beckman Coulter, Fullerton, CA).

Genome structure analysis

Oligonucleotide array-based comparative genomic hybridization (CGH) analyses were carried out using a custom-built



FIG. 1. Summary of clinical data. A, Pedigrees of six families with patients exhibiting AEXS-compatible phenotype. Families A–E are of Japanese origin, and family F is of German origin. Cases from families A–D were hitherto unreported, whereas those from families E and F have previously been described as having AEXS phenotypes (6, 8). B, Gynecomastia of six cases. C, Endocrine data in cases 15 yr of age or older. The *black*, *white*, and *red colors* represent the data in cases of the duplication, the deletion, and the inversion types, respectively; the *blue color* indicates the data of GnRH test after GnRH priming in two cases of the duplication type. The data at the time of diagnosis are denoted by *circles*, and those on aromatase inhibitor (anastrozole) treatment (1 mg/d in the duplication and the deletion types and 2–4 mg/d in the inversion types) are depicted by *squares*. The *light purple areas* represent the normal reference ranges.

oligo-microarray containing 90,000 probes for the 15q11.2-q26.3 region and approximately 10,000 reference probes for other chromosomal region (2 × 105K format, design identification 026533) (Agilent Technologies, Palo Alto, CA). The procedure was as described in the manufacturer's instructions. Fluorescence *in situ* hybridization (FISH) analysis was performed for lymphocyte or SF metaphase spreads, using long PCR products (FISH probes 1 and 2) for rearranged regions and CEP 15 probe for *D15Z4* used as an internal control (Abbott, Abbott Park, IL). The FISH probes 1 and 2 were labeled with digoxigenin and detected by rhodamine antidigoxigenin, and the CEP 15 probe was detected according to the manufacturer's protocol.

Characterization of the duplications and deletions

The duplication junctions were determined by direct sequencing for standard PCR products obtained with a variety of combinations of primers hybridizing to different positions within the *CYP19A1* exons 1 region. The deletion junctions were identified by direct sequencing of the long PCR products obtained with primer pairs flanking the deletions. The sizes of duplications and the deletions were determined by comparing obtained sequences with NT_010194 sequences at the National Center for Biotechnology Information Database (http://www.ncbi.nlm.nih.gov/; Bethesda, MD). The presence or absence of repeat sequences around the breakpoints was examined with Repeatmasker (http://www.repeatmasker.org).

For mRNA analysis, we preformed 5′-rapid amplification of cDNA ends (RACE) using a SMARTER RACE cDNA amplification kit (Takara Bio, Ohtsu, Japan). For both duplications and deletions, first PCR was carried out using the forward primer mix provided in the kit (Universal primer A mix) and an antisense reverse primer specific to *CYP19A1* exon 3 (RACE Rev). Second PCR was carried out for diluted products of the first PCR, using the nested forward primer of the kit (Nested universal primer A) and a reverse primer for *CYP19A1* exon 2 (Nested Rev). For duplications, furthermore, second PCR was also performed using various combinations of primers hybridizing to each *CYP19A1* exon 1. Subsequently PCR products were subcloned into TOPO cloning vector (Life Technologies) and subjected to direct sequencing. Then, the obtained sequences were examined with BLAST Search (National Center for Biotechnology Information). The presence or absence of promoter-compatible sequences was analyzed with the University of California, Santa Cruz, genome browser (http://genome.ucsc.edu/).

Relative mRNA levels of *CYP19A1* and its neighboring genes

We investigated relative mRNA levels of *CYP19A1* and *DMXL2* as well as those of *CGNL1*, *MAPK6*, *TMOD3*, and *TLN2* involved in the previously reported cryptic inversions (5, 8) in various human tissues. In this experiment, cDNA of SF and LCL were obtained from control males, and the remaining human cDNA samples were purchased from Life Technologies or Takara Bio. Relative quantification of mRNA against *TBP* was carried out using Taqman gene expression assay kit

TABLE 1. Summary of clinical studies in male patients with aromatase excess syndrome[a]

	Present study						Previous studies			
	Family A	Family B	Family C	Family D	Family E	Family F	Family 1	Family 2	Sporadic	
Cases	Cases 1–3	Case 4	Cases 5–6	Cases 7–9	Case 10	Cases 11–18	Two cases[b]	Proband[c]	Patient 1	Patient 2
Mutation type	Duplication	Duplication	Deletion	Deletion	Deletion	Deletion	Inversion	Inversion	Inversion	Inversion
Phenotypic findings										
Gynecomastia	Yes (mild)	Yes (mild)	Yes (moderate)	Yes (moderate)	Yes (moderate)	Yes (moderate)	Yes (severe)	Yes (severe)	Yes (severe)	Yes (severe)
Pubertal defect	Yes (mild)	Yes (mild)	Yes (mild)	No	No	Yes (mild)	N.D.	Yes (mild)	No	N.D.
Short adult height	No	No	N.D.	No	N.D.	No	Yes	N.D.	Yes	N.D.
Spermatogenesis	Preserved	N.D.	N.D.	Preserved	N.D.	Preserved	Preserved	N.D.	N.D.	N.D.
Endocrine findings										
LH (basal)	Normal	Normal	Normal	Normal/low	Normal	Normal/low	Normal	Normal/low	Normal	N.E.
LH (GnRH stimulated)[d]	Low	Normal	High	Normal	Normal	Normal	N.E.	Low	N.E.	N.E.
FSH (basal)	Low	Low	Low	Low	Low	Normal/low	Normal/low	Low	Low	N.E.
FSH (GnRH stimulated)[d]	Low	Low	Low	Low	Low	Low	N.E.	Low	N.E.	N.E.
T (basal)	Normal/low	Normal	Normal/low	Normal/low	Normal	Normal/low	Normal	Normal/low	Low	N.E.
T (hCG stimulated)[e]	N.E.	N.E.	Normal	Normal	Normal	Normal	N.E.	Normal	N.E.	N.E.
E_1 (basal)	High	High	N.E.	High	High	High	High	High	High	N.E.
E_2 (basal)	Normal	High	High	Normal	High	Normal/high	High	High	High	N.E.
E_2 to T ratio	High	High	High	High	High	High	High	High	High	N.E.

E_1, Estrone; N.D., not determined; N.E., not examined.

[a] Detailed actual data are shown in Supplemental Table 1.

[b] A father-son pair.

[c] The sister has macromastia, large uterus, and irregular menses; the parental phenotype has not been described.

[d] GnRH 100 $\mu g/m^2$ (maximum 100 μg) bolus iv; blood sampling at 0, 30, 60, 90, and 120 min.

[e] hCG 3000 IU/m^2 (maximum 5000 IU) im for 3 consecutive days; blood sampling on d 1 and 4.

(assay no. Hs00903411_m1 for *CYP19A1*; Hs00324048_m1 for *DMXL2*; Hs00262671_m1 for *CGNL1*; Hs00833126_g1 for *MAPK6*; Hs00205710_m1 for *TMOD3*; Hs00322257_m1 for *TLN2*; and Hs99999910_m1 for *TBP*). The experiments were carried out three times.

Results

CYP19A1 mRNA levels and aromatase activities

Although relative mRNA levels of *CYP19A1* and catalytic activities of aromatase were grossly similar between LCL of case 3 (family A), case 4 (family B), and case 5 (family C) and those of control subjects, they were significantly higher in SF of case 3 (family A), case 4 (family B), case 9 (family D), and case 10 (family E) than in those of control subjects (Fig. 2).

Sequence analysis of *CYP19A1*

Direct sequencing showed no mutation in *CYP19A1* coding exons 2–10 of the 10 cases examined.

Genome structure analysis

CGH analysis revealed heterozygous cryptic duplications involving most of the *CYP19A1* exons 1 region in cases from families A and B, heterozygous cryptic deletions involving most of *DMXL2* and part of *GLDN* in cases from family C, and heterozygous cryptic deletions involving most of *DMXL2* in cases from families D–F (Fig. 3A). FISH analysis supported the duplications and confirmed the deletions.

Characterization of the cryptic duplications

Aberrant PCR products were obtained with the P2 primer (which amplifies a segment between exon I.1 and exon IIa with the P1 primer) and the P3 primer (which amplifies a segment between exon I.2 and exon I.6 with the P4 primer), and sequencing of the PCR products showed the same tandem duplication involving seven of the 11 exons 1 of *CYP19A1* in cases from families A and B (Fig. 3B). The duplicated region was 79,156-bp long, and the



FIG. 2. Relative *CYP19A1* mRNA levels against *B2M* and catalytic activities of aromatase.



FIG. 3. Summary of molecular studies. For *CYP19A1*, the *dark* and *light blue lines* represent the genomic regions for noncoding exons 1 and coding exons 2–10, respectively. A, Oligoarray CGH and FISH analyses. In CGH analysis, the *black*, *red*, and *green dots* denote signals indicative of the normal, the increased (>+0.5), and the decreased (<−1.0) copy numbers, respectively. In FISH analysis, *two red signals* with an apparently different density are identified in cases from families A and B by FISH probe 1, whereas only a *single red signal* is found in cases from families C–F by FISH probe 2. The *green signals* are derived from the internal control probe. B, Schematic representation of the tandem duplication shared in common by cases 1 and 3 from family A and case 4 from family B. Genome, The junction sequence of the tandem duplication (*yellow boxes*) is shown, together with the original normal sequences at the 5′- and the 3′-ends of the duplicated region. The sequences highlighted with *light green* and *light orange* are identical, and 1 bp (A) is shared at the junction point (highlighted with *light yellow*). mRNA, The sequence of a rare clone is shown. The 3′-end of exon I.4 is connected with the 5′-end of exon I.8. C, Schematic representation of the deletion in sibling cases 5 and 6 from family C. Genome, The junction sequence of the deletion (*a gray area*) is shown. The fusion has occurred between a LINE 1 repeat sequence (*highlighted with blue*) at intron 1 of *DMXL2* and a nonrepeat sequence at intron 4 of *GLDN* and is accompanied by an addition of a 33-bp segment with a LINE 1 repeat sequence. mRNA, The sequence of a rare chimeric gene transcript is shown. *DMXL2* exon 1 consisting of a noncoding region (a *red striped box*) and a coding region (a *red box*) is spliced onto the common acceptor site (CAS) of *CYP19A1* exon 2 comprising an untranslated region (a *white box*) and a coding region (a *black box*). Thus, this transcript has two translation initiation codons (ATG), although the mRNA destined to produce a 47-amino acid protein from the ATG on *DMXL2* exon 1 is predicted to undergo NMD. D, Schematic representation of the deletion shared in common by cases 8 and 9 from family D, case 10 from family E, and cases 15 and 17 from family F. Genome, The junction sequence of the deletion (a *gray area*) is shown. The fusion has occurred between a LINE 1 repeat sequence (*highlighted with blue*) at intron 1 of *DMXL2* and that at a downstream region of *DMXL2*, with an overlap of a 12-bp segment. mRNA, The sequence of a chimeric gene transcript is delineated. The mRNA structure is the same as that described in the legend for Fig. 3C.

fusion occurred between nonrepeat elements with an overlap of one nucleotide.

All the 5′-RACE products (>500 clones) obtained from LCL and SF of case 3 (family A) and case 4 (family B) were found to be associated with a single exon 1, as observed in control materials. However, PCR amplifications for the 5′-RACE products with a variety of combinations of primers hybridizing to each exon 1 and subsequent sequencing of the PCR products revealed the presence of a chimeric clone consisting of exon I.4 at the 5′ side and exon I.8 at

the 3′ side in both LCL and SF (Fig. 3B). Although such a chimeric clone would have been produced by a splice error, this indicated that duplicated exon 1.4 at the distal nonphysiological position functioned as a transcription start site.

Characterization of the cryptic deletions

In cases from family C, long PCR products were obtained with the P7 primer and the P9 primer, and the deletion junction was determined by direct sequencing with the P8 primer (Fig. 3C). The deleted region was 211,631-bp long and involved exons 2–43 of *DMXL2* and exons 5–10 of *GLDN*. The two breakpoints resided within a LINE 1 repeat sequence and a nonrepeat sequence respectively, and a 33-bp segment with a LINE 1 repeat sequence was inserted to the fusion point. In cases from families D–F, long PCR products were obtained by sequential amplifications with the P12 primer and the P14 primer and with the P13 primer and the P14 primer, and an identical deletion was identified by direct sequencing with the P13 primer (Fig. 3D). The deletion was 165,901-bp long and involved exons 2–43 of *DMXL2*. The fusion occurred between two LINE 1 repeat sequences with an overlap of a 12-bp segment.

Sequence analysis of the 5′-RACE products obtained from LCL of cases 5 and 6 (family C) and from SF of case 9 (family D) and case 10 (family E) revealed the presence of a few clones with *DMXL2* exon 1 (2–5%), together with multiple clones with a single wild-type *CYP19A1* exon 1 (Fig. 3, C and D). Such a chimeric mRNA clone was absent from control materials. Furthermore, *DMXL2* exon 1 was found to be accompanied by a promoter-compatible sequence (Supplemental Fig. 2). This indicated a cryptic usage of *DMLX2* exon 1 as an alternative *CYP19A1* transcription start site in cases with deletions. Notably, because of the presence of the translation start codon on *DMXL2* exon 1, mRNAs of the *DMLX2/CYP19A1* chimeric genes are predicted to produce two proteins, *i.e.* CYP19A1 protein and an apparently nonfunctional 47-amino acid protein with a termination codon on *CYP19A1* exon 2, when the translation started from the initiation codons on *CYP19A1* exon 2 and on *DMLX2* exon 1, respectively. Furthermore, mRNA destined to yield the 47-amino acid protein is predicted to undergo nonsense-mediated mRNA decay (NMD) because it satisfies the condition for the occurrence of NMD (12).

Relative mRNA levels of *CYP19A1* and its neighboring genes

CYP19A1 showed a markedly high expression in the placenta and a relatively weak expression in a limited number of tissues including hypothalamus and ovary. By contrast, *DMXL2* was expressed in a range of tissues with some degree of variation as well as *CGNL1*, *MAPK6*, *TMOD3*, and *TLN2* (Fig. 4).



FIG. 4. Expression patterns of *CYP19A1* and the five neighboring genes involved in the chimeric gene formation. Relative mRNA levels against *TBP* are shown.

Discussion

We identified cryptic duplications of the *CYP19A1* promoter region and deletions of the *CYP19A1* upstream region in cases with AEXS. The tandem duplications would have caused *CYP19A1* overexpression because of an increased number of the wild-type transcription start sites. Indeed, because a rare mRNA variant with exon I.4 and exon I.8 was identified, this implies that duplicated exons 1 at the distal nonphysiological position can also function as transcription start sites. Similarly, the deletions would have caused *CYP19A1* overexpression because of a cryptic usage of *DMXL2* exon 1 with a putative promoter function as an extra transcription start site for *CYP19A1*. Indeed, because a few clones with *DMXL2* exon 1 and *CYP19A1* exon 2 were identified, this confirms the formation of a *DMXL2/CYP19A1* chimeric gene. Thus, our results suggest for the first time that duplications of a physiological promoter and deletions of an upstream region can cause overexpression of a corresponding gene and resultant human genetic disease.

Such cryptic genomic rearrangements can be generated by several mechanisms. The tandem duplication in families A and B would be formed by a replication-based mechanism of fork stalling and template switching that occurs in the absence of repeat sequences and is associated with microhomology (13). The deletion in family C is explained by nonhomologous end joining that takes place between nonhomologous sequences and is frequently accompanied by an insertion of a short segment at the fusion point (13).

The deletion in families D–F is compatible with a repeat sequence mediated nonallelic intrachromosomal or interchromosomal recombination (13). Thus, in conjunction with the previously identified four cryptic inversions that are also explainable by fork stalling and template switching or nonallelic recombination (8), genomic sequence around *CYP19A1* appears to harbor particular motifs that are vulnerable to replication and recombination errors.

To date, three types of cryptic genomic rearrangements have been identified in patients with AEXS, *i.e.* duplication type, deletion type (two subtypes), and inversion type (four subtypes) (Fig. 5). Here, although the deletion and the inversion types are associated with heterozygous impairment of neighboring genes (deletion or disconnection between noncoding exon(s) and coding exons), the phenotypes of patients are well explained by excessive *CYP19A1* activity alone. Thus, haploinsufficiency of these neighboring genes would not have a major clinical effect.



FIG. 5. Schematic representation of the rearranged genome and mRNA structures. The *white* and *black boxes* of *CYP19A1* exon 2 show untranslated region and coding region, respectively (for details, see Supplemental Fig. 1). For the duplication type and the deletion subtypes, see Fig. 3, C and D, for details. For genome, the *striped* and *painted arrows* indicate noncoding and coding exons, respectively (5′→3′). The inverted genomic regions are delineated in *blue lines*. For mRNA, *colored striped boxes* represent noncoding regions of each gene. For *TLN2*, exons A and B correspond to the previously reported exons 1 and 2 (8); because current exon 1 in the public database indicates the first coding exon, we have coined the terms exons A and B for the noncoding exons. The deletion and inversion types are associated with heterozygous impairment of neighboring genes [deletion or disconnection between noncoding exon(s) and the following coding exons]. The inversion subtype 1 is accompanied by inversion of eight of the 11 *CYP19A1* exons 1, and the inversion subtype 2 is associated with inversion of the placenta-specific *CYP19A1* exon I.1.

For the deletion and inversion types, two factors should be considered. One factor is expression patterns of each chimeric gene. In this regard, the five genes involved in the formation of chimeric genes are widely expressed, with some degree of variation (Fig. 4). Furthermore, *in silico* analysis revealed promoter-compatible sequences around exon 1 of *DMXL2*, *CGN1*, *MAPK6*, and *TMOD3* in multiple cell types, although such sequences remain to be identified for noncoding exons of *TLN2* (Supplemental Fig. 2). These findings imply that the chimeric genes show wide expression patterns because expression patterns of chimeric genes would follow those of the original genes.

The other factor is expression dosage of each chimeric gene. In this context, the *DMXL2/CYP19A1* chimeric mRNA was identified only in 2–5% of transcripts from SF, whereas the *CGNL1/CYP19A1* chimeric mRNA and the *TMOD3/CYP19A1* chimeric mRNA accounted for 89–100% and 80% of transcripts from SF, respectively (no data for the *MAPK6/CYP19A1* and the *TLN2/CYP19A1* chimeric genes) (5). This difference is obviously inexplicable by the relative expression level in SF that is grossly similar between *DMXL2* and *TMOD3* and is quite low for *CGNL1* (Fig. 4). In this regard, it is notable that a translation start codon and a following coding region are present on exon 1 of *DMXL2* (Fig. 5). It is likely that *DMXL2/CYP19A1* chimeric mRNA transcribed by the *DMXL2* promoter preferentially recognized the natural start codon on *DMXL2* exon 1 and underwent NMD and that rather exceptional chimeric mRNAs, which recognized the start codon on *CYP19A1* exon 2, were identified by 5′-RACE. By contrast, such a phenomenon would not be postulated for the inversion-mediated chimeric mRNA because of the absence of a translation start codon on the fused exon 1 of *CGNL1* and *TMOD3* (as well as exon 1 of *MAPK6* and exons A and B of *TLN2*) (Fig. 5). For the *CGNL1/CYP19A1* chimeric gene, furthermore, the physical distance between *CGNL1* exon 1 and *CYP19A1* exon 2 is short, and whereas a splice competition may be possible between exon 1 of neighboring genes and original *CYP19A1* exons 1, eight of 11 *CYP19A1* exons 1 including exon I.4 functioning as the major promoter in SF have been disconnected from *CYP19A1*-coding exons by inversion. These structural characters would have also contributed to the efficient splicing between *CGNL1* exon 1 and *CYP19A1* exon 2 (14). In this context, although the *CGNL1/CYP19A1* chimeric gene is associated with functional loss of eight *CYP19A1* exons 1 and the resultant reduction of *CYP19A1* expression in *CYP19A1*-expressing tissues, overall aromatase activity would be increased

by the wide expression of the chimeric gene. These structural properties would primarily explain the difference in the expression dosage of chimeric mRNA between the deletion and the inversion types.

It is inferred, therefore, that the duplication type simply increases *CYP19A1* transcription in native *CYP19A1*-expressing tissues, whereas the deletion and the inversion types cause relatively mild and severe *CYP19A1* overexpression in a range of tissues, respectively. These notions would grossly explain why clinical features of affected males and carrier females and endocrine profiles of affected males are apparently milder in the duplication and the deletion types than in the inversion type and why clinical findings were ameliorated with 1 mg/d of anastrozole in the duplication and the deletion types and with 2–4 mg/d of anastrozole in the inversion type. In addition, the different expression pattern between *CYP19A1* and *DMXL2* may explain, in terms of autocrine and/or paracrine effects, why phenotypic features such as gynecomastia tended to be more severe in the deletion type than in the duplication type under similar endocrine profiles.

Furthermore, several findings are notable in this study. First, a similar degree of FSH-dominant hypogonadotropic hypogonadism is present in the three types, with no amelioration of FSH responses to GnRH stimulation after GnRH priming in two cases with the duplication. This suggests that a relatively mild excess of circulatory estrogens, as observed in the duplication and the deletion types, can exert a strong negative feedback effect on FSH secretion, primarily at the pituitary, as has been suggested previously (15–19). Second, although basal T values appear to be mildly and similarly compromised in the three types, age-matched comparison suggests that T responses to hCG stimulation are apparently normal in the duplication and the deletion types and somewhat low in the inversion type. These data, although they remain fragmentary, would primarily be compatible with fairly preserved LH secretion in the three types and markedly increased estrogen values in the inversion type because T production is under the control of LH (1), and excessive estrogens compromise testicular steroidogenic enzyme activity (20, 21). Lastly, although testis volume appears somewhat small, fertility (spermatogenesis) is normally preserved in the three types. This would be consistent with the FSH-dominant hypogonadotropic hypogonadism because FSH plays only a minor role in male fertility (spermatogenesis) (22). Indeed, males with mutations of *FSHR* encoding FSH receptor as well as mice lacking *FSHB* or *FSHR* can be fertile (23, 24).

The results of this study are contrastive to those of the previous studies. In the previous studies, inversions only have been identified, and each inversion is specific to each family or patient (8). By contrast, in this study, the identical duplication was found in two Japanese families A and B, and the same deletion (subtype 2 in Fig. 5) was shared by three Japanese and one Caucasian families D–F, despite apparent nonconsanguinity. This may be explained by assuming that patients with severe phenotype were preferentially examined in the previous studies, whereas those with the AEXS phenotype were analyzed in this study without ascertainment bias. Furthermore, because phenotypes are milder in the duplication and the deletion types than in the inversion type, this may have permitted the spread of the duplication and the deletion types, but not the inversion type, as the founder abnormalities. This notion predicts that the duplication and the deletion types would be identified by examining patients with mild AEXS phenotype.

In summary, the present study shows that AEXS can be caused by duplications of the physiological promoters and microdeletions of the upstream regions of *CYP19A1* and that phenotypic severity is primarily determined by the tissue expression pattern of *CYP19A1* and the chimeric genes and by structural properties of the fused exons. Most importantly, the present study provides novel models for the gain-of-function mutations leading to human genetic disease.

Acknowledgments

Address all correspondence and requests for reprints to: Dr. Tsutomu Ogata, Department of Molecular Endocrinology, National Research Institute for Child Health and Development, 2-10-1 Ohkura, Setagaya, Tokyo 157-8535, Japan. E-mail: tomogata@nch.go.jp.

Present address for T.O.: Department of Pediatrics, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan.

This work was supported by Grants for Research on Intractable Diseases (H22-035 and H22-098) from the Ministry of Health, Labor, and Welfare; Grants-in-Aid for Scientific Research (B) (20390265) and (S) (22227002) from the Japan Society for the Promotion of Science; and Grant-in-Aid for Scientific Research on Innovative Areas (22132004) from the Ministry of Education, Culture, Sports, Science, and Technology.

Disclosure Summary: The authors have nothing to declare.

References

1. **Bhasin S** 2008 Testicular disorders. In: Kronenberg HM, Melmed M, Polonsky KS, Larsen PR, eds. Williams textbook of endocrinology. 11th ed. Philadelphia: Saunders; 645–699
2. **Bulun SE, Takayama K, Suzuki T, Sasano H, Yilmaz B, Sebastian S**

2004 Organization of the human aromatase p450 (CYP19) gene. Semin Reprod Med 22:5–9
3. **Demura M, Reierstad S, Innes JE, Bulun SE** 2008 Novel promoter I. 8 and promoter usage in the CYP19 (aromatase) gene. Reprod Sci 15:1044–1053
4. **Harada N, Utsumi T, Takagi Y** 1993 Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinogenesis. Proc Natl Acad Sci USA 90:11312–11316
5. **Shozu M, Sebastian S, Takayama K, Hsu WT, Schultz RA, Neely K, Bryant M, Bulun SE** 2003 Estrogen excess associated with novel gain-of-function mutations affecting the aromatase gene. N Engl J Med 348:1855–1865
6. **Binder G, Iliev DI, Dufke A, Wabitsch M, Schweizer R, Ranke MB, Schmidt M** 2005 Dominant transmission of prepubertal gynecomastia due to serum estrone excess: hormonal, biochemical, and genetic analysis in a large kindred. J Clin Endocrinol Metab 90: 484–492
7. **Martin RM, Lin CJ, Nishi MY, Billerbeck AE, Latronico AC, Russell DW, Mendonca BB** 2003 Familial hyperestrogenism in both sexes: clinical, hormonal, and molecular studies of two siblings. J Clin Endocrinol Metab 88:3027–3034
8. **Demura M, Martin RM, Shozu M, Sebastian S, Takayama K, Hsu WT, Schultz RA, Neely K, Bryant M, Mendonca BB, Hanaki K, Kanzaki S, Rhoads DB, Misra M, Bulun SE** 2007 Regional rearrangements in chromosome 15q21 cause formation of cryptic promoters for the CYP19 (aromatase) gene. Hum Mol Genet 16:2529–2541
9. **Tiulpakov A, Kalintchenko N, Semitcheva T, Polyakov A, Dedov I, Sverdlova P, Kolesnikova G, Peterkova V, Rubtsov P** 2005 A potential rearrangement between CYP19 and TRPM7 genes on chromosome 15q21.2 as a cause of aromatase excess syndrome. J Clin Endocrinol Metab 90:4184–4190
10. **Stratakis CA, Vottero A, Brodie A, Kirschner LS, DeAtkine D, Lu Q, Yue W, Mitsiades CS, Flor AW, Chrousos GP** 1998 The aromatase excess syndrome is associated with feminization of both sexes and autosomal dominant transmission of aberrant P450 aromatase gene transcription. J Clin Endocrinol Metab 83:1348–1357
11. **Bellino FL, Osawa Y** 1977 Localization of estrogen synthetase in the chorionic villus fraction after homogenization of human term placenta. J Clin Endocrinol Metab 44:699–707
12. **Kuzmiak HA, Maquat LE** 2006 Applying nonsense-mediated mRNA decay research to the clinic: progress and challenges. Trends Mol Med 12:306–316
13. **Gu W, Zhang F, Lupski JR** 2008 Mechanisms for human genomic rearrangements. Pathogenetics 1:4
14. **Castillo-Davis CI, Mekhedov SL, Hartl DL, Koonin EV, Kondrashov FA** 2002 Selection for short introns in highly expressed genes. Nat Genet 31:415–418
15. **Shaw ND, Histed SN, Srouji SS, Yang J, Lee H, Hall JE** 2010 Estrogen negative feedback on gonadotropin secretion: evidence for a direct pituitary effect in women. J Clin Endocrinol Metab 95:1955–1961
16. **Belgorosky A, Guercio G, Pepe C, Saraco N, Rivarola MA** 2009 Genetic and clinical spectrum of aromatase deficiency in infancy, childhood and adolescence. Horm Res 72:321–330
17. **Alexander DC, Miller WL** 1982 Regulation of ovine follicle-stimulating hormone β-chain mRNA by 17β-estradiol *in vivo* and *in vitro*. J Biol Chem 257:2282–2286
18. **Mercer JE, Clements JA, Funder JW, Clarke IJ** 1988 Luteinizing hormone-β mRNA levels are regulated primarily by gonadotropin-releasing hormone and not by negative estrogen feedback on the pituitary. Neuroendocrinology 47:563–566
19. **Raven G, de Jong FH, Kaufman JM, de Ronde W** 2006 In men, peripheral estradiol levels directly reflect the action of estrogens at the hypothalamo-pituitary level to inhibit gonadotropin secretion. J Clin Endocrinol Metab 91:3324–3328
20. **Moger WH** 1980 Direct effects of estrogens on the endocrine function of the mammalian testis. Can J Physiol Pharmacol 58:1011–1022
21. **Strauss L, Kallio J, Desai N, Pakarinen P, Miettinen T, Gylling H, Albrecht M, Mäkelä S, Mayerhofer A, Poutanen M** 2009 Increased exposure to estrogens disturbs maturation, steroidogenesis, and cholesterol homeostasis via estrogen receptor α in adult mouse Leydig cells. Endocrinology 150:2865–2872
22. **Kumar TR, Wang Y, Lu N, Matzuk MM** 1997 Follicle stimulating hormone is required for ovarian follicle maturation but not male fertility. Nat Genet 15:201–204
23. **Tapanainen JS, Aittomäki K, Min J, Vaskivuo T, Huhtaniemi IT** 1997 Men homozygous for an inactivating mutation of the follicle-stimulating hormone (FSH) receptor gene present variable suppression of spermatogenesis and fertility. Nat Genet 15:205–206
24. **Layman LC, McDonough PG** 2000 Mutations of follicle stimulating hormone-β and its receptor in human and mouse: genotype/phenotype. Mol Cell Endocrinol 161:9–17

日本小児科学会雑誌　115巻1号　1～4（2011年）

総　説

日本の性分化疾患の実情

I. 性分化疾患の実態調査結果

山梨大学大学院医学工学総合研究部，日本小児内分泌学会性分化委員会

大　山　建　司

キーワード：性分化疾患，実態調査，性腺

はじめに

性分化の異常を有する症例は，疾患の性質上また社会通念上，隠蔽される傾向にあり，長くその実態は明らかにされてこなかった．しかし近年，性分化機構の解明が飛躍的に進歩し，疾患の原因が明らかになるにつれて，疾患への関心が高まり，患者が抱える様々な問題点も注目されるようになってきた．このような社会環境の変化の中で，我が国でも従来使用されてきた疾患名の見直し，性分化疾患の実態把握，社会的緊急性が高い新生児期の初期対応が日本小児内分泌学会を中心に検討されている．本稿で述べる性分化疾患の実態調査，初期対応は表1に示す組織が合同で行ったものである．

疾患名の削除・変更

従来，インターセックス（間性），半陰陽（雌雄同体），仮性半陰陽等と呼ばれていた疾患は，総称して性分化異常症と呼ばれていた．しかしこれらの用語には倫理的問題や侮蔑的な意味合いを含むものもあり，命名法の再検討が必要と考えられるようになった[1,2]．2006年性分化異常症の専門家による国際会議が開催され，新たな英文病名が提唱された．その結果，Disorders of Sex Differentiation は Disorders of Sex Development（DSD）に変更された．この国際会議におけるコンセンサスの詳細は緒方が報告している[3]．これに伴い，2009年第43回日本小児内分泌学会総会で，日本語病名を性分化異常症から性分化疾患に変更することを決定し，周知していくこととなった．

性分化疾患は，「染色体，性腺，または解剖学的性が非定型である先天的状態」と定義されている．一方，性同一性障害は定まった定義はできていないが，一般的には，生物学的に男女いずれかの身体的形状を有するにもかかわらず，性自認が生物学的性と一致しない状態とされている．ここでいう性自認は，染色体，性腺，ホルモン，内性器，外性器，ジェンダー，性役割・性指向のいずれからも独立していることが条件とされている．性分化疾患に伴う性同一性障害は一般的な性同一性障害とは分けて分類されている．

性分化疾患の用語の中で，今後使用すべきではないと考えている疾患名としては，前述したインターセックス（間性），半陰陽（雌雄同体），仮性半陰陽以外に，類宦官症（低または高ゴナドトロピン性類宦官症），睾丸性女性化症，副腎性器症候群が挙げられている．真性半陰陽は卵精巣性性分化疾患，男性または女性仮性半陰陽は，新たな用語となる46, XY または46, XX性分化疾患に含まれる．卵巣に対応する呼称として睾丸は精巣に改める（停留精巣，精巣形成不全，精巣機能低下症等）．

性分化疾患の実態調査

我が国における性分化疾患の実態はこれまで，一部の疾患を除いて明らかにされていなかった．今回，日本小児内分泌学会性分化委員会（委員長：大山建司）と厚生労働省難治性疾患克服研究事業（研究代表者：緒方勤）が合同で，日本小児内分泌学会と日本小児泌尿

連絡先住所：（〒409-3898）中央市下河東1110
山梨大学医学部看護学科成育看護学
大山　建司

表1　性分化疾患の実態調査，初期対応の検討を行った組織

1. 日本小児内分泌学会性分化委員会
（大山建司，緒方勤，有阪治，堀川玲子，位田忍，立花克彦，向井徳男，佐藤清二，木下英一）
2. 厚生労働科学研究費補助金，難治性疾患研究事業
1）性分化疾患の実態把握と治療指針作成班（緒方勤，大山建司，堀川玲子，藤枝憲二，有阪治，島田憲次，野々村克也）
2）チトクローム P450 オキシドレダクターゼ異常症の実態把握と治療指針作成班（深見真紀）
3）副腎ホルモン産生異常に関する調査研究班（藤枝憲二）

表2　性腺の発生分化に関連する性分化疾患

	小児科領域		小児泌尿器科領域		合計	
疾患名	確診	疑い	確診	疑い	確診	疑い
性腺形成障害（原因不明）	10	18	1	3	11	21
卵精巣性性分化疾患（真性半陰陽）	26	2	22	0	48	2
XY 性腺形成異常症	7	2	2	1	9	3
XX 性腺形成異常症	3	1	0	0	3	1
XX 男性（SRY +）	4	2	5	0	9	2
XX 男性（SRY −）	6	0	3	0	9	0
XY 女性（SRY 異常あり）	6	0	0	0	6	0
XY 女性（SRY 異常なし）	7	1	0	0	8	1
上記以外の性染色体異常（ターナー症候群を除く）	77	2	21	0	98	2
WT1 異常症	20	3	10	0	30	3
SF1 異常症	6	0	0	0	6	0
DAX1 異常症	38	3	0	1	38	4
SOX9 異常症	3	1	1	0	4	1
DHH（desert hedgehog）異常症	0	0	0	0	0	0
9p 欠失	1	0	0	0	1	0
ARX 異常症（XLAG）	0	0	0	0	0	0
ATRX	5	1	0	0	5	1
ATR-16	0	0	0	0	0	0
10q25-Cter 欠失	1	1	0	0	1	1
WNT4/RSPO1 過剰発現	0	0	0	0	0	0
WNT4 異常症	0	0	0	0	0	0
RSPO1 異常症	0	0	0	0	0	0
高次脳機能障害を伴う性分化異常症	2	1	0	0	2	1
小脳失調を伴う性分化異常症	4	0	0	0	4	0
合計	226	38	65	5	291	43

器科学会の全学会員 1,911 名を対象として調査を行った．集計は施設毎に行った．施設数は小児内分泌 326 施設，小児泌尿器 166 施設であった．調査に当っては従来一般的に使用されている疾患名を併記した．調査結果を表 2〜5 に示す．生殖器奇形は，出生 4,500 人に 1 例の頻度と推定されている．今回の調査対象からターナー症候群は除いた．ターナー症候群は出生女児 2,500 人に 1 人の頻度と推定されている[4]．

性腺の発生・分化に関連する性分化疾患（表 2）では，確診例の中で卵精巣性性分化疾患 3 例，上記以外の性染色体異常 3 例，WT1 異常症 2 例が重複例と推測されたため，確診例総数は 283 例，疑い例 43 例である．確診例の中では，卵精巣性性分化疾患，DAX1 異常症，WT1 異常症が多数を占めた．卵精巣性性分化疾患の染色体核型は 46, XX が 60% 以上と頻度が高く，次いで 46, XX/46, XY キメラが 20%，46, XY は 10% 以下と

表3 46, XY性分化疾患

	小児科領域		小児泌尿器科領域		合計	
疾患名	確診	疑い	確診	疑い	確診	疑い
原因不明の46XY性分化異常	46	53	11	2	57	55
GnRH受容体異常症	0	0	0	2	0	2
GPR54異常症	0	0	0	0	0	0
LH異常症	0	0	0	1	0	1
FSH異常症	0	0	0	1	0	1
LH受容体異常症	2	1	1	0	3	1
アンドロゲン受容体異常症	43	19	20	9	63	28
Smith-Lemli-Opitz症候群	3	0	2	0	5	0
Aaskog-Scott症候群	3	3	0	0	3	3
Robinow症候群	2	3	1	0	3	3
胎児期精巣退縮症候群	22	10	51	9	73	19
ミュラー管遺残症候群	2	2	4	2	6	4
尿道下裂（CXorf6, BMP4, BMP7, HOXA4, HOXB6, HOXA13異常）	3	0	0	0	3	0
合計	126	91	90	26	216	117

表4 46, XX性分化疾患

	小児科領域		小児泌尿器科領域		合計	
疾患名	確診	疑い	確診	疑い	確診	疑い
原因不明の46XX性分化異常	1	1	1	0	2	1
卵巣形成不全，無形成	7	0	0	0	7	0
子宮形成不全，無形成 Mayer-Rokitansky-Kuster（MRK）症候群	8	3	3	6	11	9
子宮形成不全，無形成 MURCS（Mullerian, renal, cervical spine）	0	2	0	0	0	2
子宮形成不全，無形成 MODY5に合併	0	0	0	0	0	0
子宮形成不全，無形成その他	2	1	1	0	3	1
腟形成不全 McKusck-Kaufman症候群（BBS6）	0	0	1	0	1	0
腟形成不全 hannd-foot-genital症候群（HOXA13）	0	0	0	0	0	0
腟形成不全その他	3	1	2	2	5	3
合計	21	8	8	8	29	16

報告されている[5]．小脳失調を伴う性分化疾患が4例報告され，新たな疾患群となる可能性がある．表2に「上記以外の性染色体異常」が100例報告されており，詳細は不明だがクラインフェルター症候群が含まれている可能性はある．

46, XY性分化疾患（表3）ではアンドロゲン受容体異常症4例，LH受容体異常症1例が重複例と推測された．全体で確診例211例，疑い例117例である．泌尿器科領域では胎児期精巣退縮症候群，小児科領域ではアンドロゲン受容体異常症が多数を占めていた．両側精巣の胎児期精巣退縮症候群は出生男児20,000人に1人と報告されている[6]．アンドロゲン受容体異常症は出生男児20,000～99,000人に1人と報告されているが[7][8]，遺伝子診断が普及してきたため，発生頻度は今後増加する可能性がある．

46, XX性分化疾患（表4）では，MRK症候群1例，腟形成不全その他の1例が重複していると思われる．重複例を除くと確診例27例，疑い例16例で，総数は43例である．46, XX性分化疾患の大部分は後述する先天性副腎過形成症が占める．それ以外の46, XX性分化疾患は，新生児期に外性器異常を伴わない症例（完全女性型）が多く存在するため，思春期以降に婦人科を受診する可能性も高く，そのような症例は婦人科を調査対象としていない今回の調査からは漏れている可能

表5　性ステロイド合成系にかかわる性分化疾患，その他

	小児科領域		小児泌尿器科領域		合計	
疾患名	確診	疑い	確診	疑い	確診	疑い
先天性副腎過形成症（下記以外または詳細不明）	89	15	33	1	122	16
StAR 異常症	29	1	0	0	29	1
コレステロール側鎖切断酵素（P450scc）欠損	1	0	0	0	1	0
先天性リポイド副腎過形成症	12	4	1	0	13	4
3β-水酸化ステロイド脱水素酵素（HSD3B2）欠損	7	2	1	0	8	2
17α-水酸化酵素（CYP17）欠損（17, 20-lyase 欠損）	5	1	1	0	6	1
POR（P450 oxidoreductase）欠損	24	2	0	0	24	2
17β-水酸化ステロイド脱水素酵素（HSD17B3）欠損	0	0	2	0	2	0
5α-還元酵素（SRD5A2）欠損	8	2	0	1	8	3
21-水酸化酵素（CYP21A2）欠損	644	27	46	0	690	27
11β-水酸化酵素（CYP11B1）欠損	21	4	6	0	27	4
アロマターゼ（CYP19）欠損	0	0	0	1	0	1
IMAge 症候群	2	2	0	0	2	2
表2～5以外の性分化異常と思われる疾患	16	2	2	0	18	2
合計	858	62	92	3	950	65

性がある．

性ステロイド合成系にかかわる性分化疾患を表5に示す．確診例は小児科領域858例，泌尿器科領域92例である．詳細不明の先天性副腎過形成症確診例が122例あり，この大部分は21-水酸化酵素欠損症と推測される．また，泌尿器科から報告された先天性副腎過形成，21-水酸化酵素欠損症の大部分は重複例と考えられる．以上より，21-水酸化酵素欠損症確診例は733例，疑い例42例，合計775例と判断した．先天性リポイド副腎過形成症1例，17α-水酸化酵素欠損症1例は重複例と考えられる．3β-水酸化ステロイド脱水素酵素欠損症と11β-水酸化酵素欠損症は報告された施設から重複例ではないと判断した．以上より，表5の報告例の中で重複例を除く確診例の総数は821例となり，疑い例を含めると881例となる．表2～5に該当しない性分化疾患は確診例18例，疑い例2例存在した．

全体をまとめると，今回の調査で報告された性分化疾患の確診例総数は1,360例，疑い例総数は238例，合計1,598例である．POR 異常症の遺伝子診断を行った国立医療センターの深見の把握している症例数は38例であり，今回の調査で63%（24例）が把握された．藤枝らが行った調査での先天性副腎過形成症1,316例を基準にしても，今回の回収率は65%とほぼ同様であった．回収率を60%とすれば，小児領域(20歳未満)のターナー症候群を除く性分化疾患は2,500～3,000人と推定される．これは20歳未満の人口比で10,000人に約1.3人となる．

文　献

1) Frader J, Alderson P, Asch A, et al. Health care professionals and intersex conditions. Arch Pediatr Adolesc Med 2004；158：426—429.
2) Conn J, Gillam L, Conway G. Revealing the diagnosis of androgen insensitivity syndrome in adulthood. BMJ 2005；331：628—630.
3) 緒方　勤，堀川玲子，長谷川奉延，他．性分化異常症の管理に関する合同見解．日児誌　2008；112：565—578.
4) Styne DM, Grumbach MM. Syndrome of Gonadal Dysgenesis and its Variants (Turner Syndrome). In：Kronenberg HM, Melmed A, Polomsky KS, et al, eds. Williams Textbook of Endocrinology. 11 ed. Philadelphia：Sounders, 2008：1055.
5) Krob G, Braun A, Kuhnle U. True hermaphroditism：geographical distribution, clinical findings and gonadal histology. Eur J Pediatr 1994；153：2—10.
6) Borrow M, Gough M. Bilateral absence of the testes. Lancet 1970；1：366.
7) Banksboll S, Qvist I, Lebech PE, et al. Testicular feminization syndrome and associated gonadal tumours in Denmark. Acta Obstet Gynecol Scand 1992；71：63—66.
8) Boehmer AL, Brinkmann AO, Bruggenwirth H, et al. Genotype versus phenotype in families with androgen insensitivity syndrome. J Clin Endocrinol Metab 2001；86：4151—4160.

日本小児科学会雑誌　115巻1号　5～12（2011年）

Ⅱ．性分化疾患の初期対応

国立成育医療研究センター内分泌代謝科

堀　川　玲　子

キーワード：性分化疾患

性分化疾患診療合意文書（Consensus guidelines）を受けて

2006年に米国小児内分泌学会（Lawson-Wilkins Pediatric Endocrine Society（LWPES：現 Pediatric Endocrine Society））とヨーロッパ小児内分泌学会（European Society for Pediatric Endocrinology（ESPE））が中心となり，世界の性分化疾患診療の専門家が集まって性分化疾患診療合意文書が作成された．

これを受け，日本小児内分泌学会性分化委員会ではこの合意文書の邦訳を2008年に完成させた．次のステップとして，同委員会と厚生労働科学研究費難治性疾患克服研究事業性分化異常に関する研究班が合同で，初期対応について診療の手引きを作成した．

外性器異常を有する児が出生した時にまず問題となるのは，適切な社会的性の選択と親に対する対応である．本邦では後に述べるように戸籍法が制定されており，男女の性の選択と登録が義務づけられている．また，法制だけでなく，実際の社会生活を送る上で男女の性を選択することが欠かせず，「中間の性」といった社会通念はまだ形成されていない．さらに，一度戸籍に登録された性を変更するには家庭裁判所の判断が必要になり，社会的/文化的に性変更が受容される環境が整っていない場合が多い．これらの事由で，初期の社会的性の決定が適切になされることは重要で，このためには適切な診断と治療方針の策定がなされなければならない．診断や治療方針の策定などの判断は必ずしも容易ではなく，現時点での判断が将来妥当であったと判断されるかどうかも，不確定の部分は存在する．そのような条件の下で，現在行い得る診療の標準化を図ることは，性分化疾患の児の予後を改善するための喫緊の課題である．

初期対応として重要なもう一つの点は，親への対応である．一般に，疾患を有する新生児を持った親に対しては，疾患に対する十分な理解が得られるような情報の提供と心理的ケアが必要である．性別がすぐに判定できない状況は，命名の保留につながり，親には混乱が生じる可能性がある．児に対する愛着形成が障害されないよう，親に対する説明に使用する言葉も十分に配慮がなされなければならない．

上述の合意文書は，欧米の文化に基づいたものであるが，ほとんどは本邦でも共通の理解と考えられる．しかしながら，初期対応にどのような言葉を使用するか，どのような言葉を使用すべきではないか，といった点は，言語自体と文化的背景の機微を理解していないと困難である．

このような目的で初期対応が策定された．

「初期対応の手引き」の構成

1）1頁目に，性分化疾患の概要を記した．定義，主症状，緊急に対応すべき身体状況，そして最も伝えたいメッセージとして，「**性分化疾患は，その取り扱いについて経験の豊富な施設で扱うべき疾患である．**」と明記した．このメッセージに使用する文言については，委員会内で最も議論があったところであるが，性分化疾患初期対応の標準化を図るには，集約化が最も適切な方法であるということで一致した．

2）2頁目以降は初期対応の実際について，以下の項目に沿って表で提示した．

- 日齢（月齢）
- 診断と治療：診断に必要な検査，必要な治療
- 医療者間：経験豊富な施設の専門家へのコンサルト，（両）親への説明窓口の一本化，複数科（時に複数施設）の参加したチーム医療の必要性，可能であれば心理介入を初期から開始することが望ましいこと
- 保護者への対応：「説明時の表現（提言），しておきたいこと」「避けたい表現・行動」に分けて提示．

保護者への説明に最も重要であると考えたのは，①虚偽を述べないこと，②わかりうる情報を可能な限り提示し共有する，③「わからない」「不完全」「異常」といった不安を与える，あるいはネガティブな表現は使用しない，④診断を変更することのないよう，安易な説明はしない，ということである．説明時の表現とし

連絡先住所：（〒157-8535）世田谷区大蔵2—10—1
国立成育医療研究センター内分泌代謝科
堀川　玲子

て,「外性器の成熟が遅れている」という表現を提示した.「未熟である」という表現よりも治療の可能性を示唆した緩やかな表現を目指した. 疾患名(性分化疾患)と状態については, 日本人の親の性向やインターネットの発達による情報取得の可能性から, 医学的な表現で正確に伝えた方がよいと考えた. また, 家族内での責任者の議論が起こらないよう配慮し説明することも大切である.

3) その他

- 早産児の取り扱い上の注意, 特に注意すべき検査結果の解釈
- 必要な検査項目, 泌尿器科（外科）的治療プランと診断のアルゴリズム
- 付則として, 戸籍法とその解釈, 適用

戸籍法については, 出生届における性別, 名前の保留が可能であることを明記し, 周知するようにした. 性同一性障害と性分化疾患は同じではないことを記し, 性同一性障害で設けられている事項も参考として記載した.

初期対応の手引きの使い方

性分化疾患の取り扱いについては, 初期対応のみならず治療法を含めた長期のケアについても, 最終的には個別の対応が必要となる. それを充分念頭に入れて, 手引きとして用いてもらうのが作成の意図の一つである.

これまでに性分化疾患を多く取り扱ってきた専門家達が, 文献及び自らの反省も含めた経験から作成した手引きであるので, 現在の日本の状況を鑑みて妥当であると考えている. 社会的性決定や性腺の取り扱いには, 様々な意見があるので, 今後適宜議論と改訂を重ねて行ければと考えている.

謝辞　本研究の一部は, 厚生労働科学研究費補助金難治性疾患克服研究事業「性分化疾患に関する研究」班により助成を受けた.

性分化疾患初期対応の手引き Ver7　062510

日本小児内分泌学会性分化委員会
厚生労働科学研究費補助金難治性疾患克服研究事業
性分化疾患に関する研究班

性分化疾患とは

卵巣・精巣や性器の発育が非典型的である状態

性分化疾患を疑う所見

外性器所見が典型的男児/女児とは以下の点で異なる.

1. 性腺を触知するか？：停留精巣など
2. 陰茎あるいは陰核の状態：矮小陰茎あるいは陰核肥大か？
   ＊亀頭が露出していれば陰核肥大を疑うが，露出していなくても陰核肥大でないとは言えない.
3. 尿道口の開口部位：尿道下裂あるいは陰唇癒合がないか？　通常の位置と異ならないか？
4. 陰嚢あるいは陰唇の状態：陰嚢低形成あるいは大陰唇の男性化（肥大し皺がよる）がないか？
5. 膣の状態：膣盲端（dimple のみの形成もあり）や，泌尿生殖洞（尿道口と共通になる）はないか？
6. 色素沈着はないか？

性分化疾患に合併する，早急に確認すべき所見：急性副腎不全・急性腎不全

1. 血清電解質異常（低ナトリウム，高カリウム血症）
2. 発症は数日遅れることがある.

性分化疾患は，その取り扱いについて経験の豊富な施設で扱うべき疾患である.

性分化疾患初期対応

日齢	診断・治療	医療者間	保護者への対応	
			説明時の表現（提案）・しておきたいこと	避けたい表現・行動
出生時	・生命予後に直結する疾患の鑑別（副腎疾患等） ・外科的疾患に対する対応 ・早産児に対する対応*1 ・診察：外性器の形態(陰茎/陰核ｓ長，尿道口/膣口の開口と位置など)，性腺を触知するか ・血液・尿検査：17-OHP（濾紙血も）	・性分化疾患に関わる医療者の召集/専門家へのコンサルト開始 ・施設内で保護者への説明内容の統一（説明者を決めた方がよい） ・経験豊富な施設へのコンサルト・転院も考慮（小児内分泌学会 HP 参照） ・心理介入開始が望ましい．	・「外性器の成熟が遅れています．**性分化疾患が疑われます．**」 ・「性分化疾患とは，卵巣・精巣や性器の発育が非典型的となるものです」 ・「性別については，検査をして判断をしましょう」 ・診断までの期間等初期の見通しを説明する．「検査の結果が出るまでには1週間以上必要です．追加検査が必要になることもあります．2週間以内に結果が出せるように計画しますが，必ず全ての結果が揃うとは限りません．」 ・説明時には，両親がいる場合は両親揃っていること． ・祖父母への対応：児の状態の理解と両親への支援を促す． ・児の問題点が性の分化に関わることだけであれば（副腎・腎等の合併症がなければ），他は健常であることを積極的に伝える． ・家族内で誰の責任である，という議論にならないように，特に産褥期の母親のメンタリティーに配慮し，責められることがないように十分に説明する．	・「男の子か女の子か**わからない**」 ・「不完全」「異常」という言葉は使わない． ・**その場で**最も可能性のある性を安易に告げない．
～7日まで	・染色体検査（SRY，G-banding） ・性腺・内性器の検索（超音波検査，MRI，尿道造影，腹腔鏡，性腺生検等） ・血液・尿検査*2 ・原疾患の診断（可能な限り） ・合併症の検索（副腎/腎疾患等） ・遺伝子検査	・社会的性の判定*3 ・社会的性選択と疾患予後に関わる多因子を考慮した診療計画策定（泌尿器科的治療・内科的治療の内容と時期）*4． ・原疾患の治療 ・心理カウンセリング ・性別判定までは入院継続を考慮	・出生時の説明の反復・理解の確認 ・出生届の保留（保留可能であることの周知)「出生届は急ぐ必要はありません」「期限延長が可能です」 ・医療保険が問題となる場合「性別・名前保留で提出が可能」 ・検査結果が揃って解釈可能となったところで説明することが望ましい． ・医療者からの社会的性別の提言と診療計画の説明を行い，両親を含め検討．両親の希望を充分汲み取る．	・「わからない」は避ける ・「不完全」「異常」という言葉は使わない． ・出生届を急がせることは避ける． ・検査結果を個々に説明することを避ける．特に染色体検査結果のみ説明することはしない．
～14日まで	・性腺・内性器の検索（超音波検査，MRI，尿道造影，腹腔鏡，性腺生検等） ・HCG 負荷試験*5 ・原疾患の診断（可能な限り） ・合併症の検索（副腎/腎疾患等） ・遺伝子検査	・社会的性の判定*3，判定に苦慮する症例については集学的チームによる判断を検討する． ・社会的性選択と疾患予後に関わる多因子を考慮した診療計画策定（泌尿器科的治療・内科的治療の内容と時期）*4． ・原疾患の治療 ・心理カウンセリング ・性別判定までは入院継続を考慮	・出生時の説明の反復・理解の確認 ・出生届（名前，性別）の保留（保留可能であることの周知)「出生届は急ぐ必要はありません」「期限延長もやむを得ない場合は可能です」 ・医療保険が問題となる場合や家族の心理状態などを鑑みて必要のある場合，「性別・名前保留で提出が可能」であることを伝える． ・検査結果が揃って解釈可能となったところで説明することが望ましいが，経過時間を配慮し，この時点での検査結果に基づいた説明を行う． ・診断がついた場合，医療者からの社会的性別の提言と診療計画の説明を行い，両親を含め検討．両親の希望を充分汲み取る． ・診療計画については，あらゆる治療の可能性と性自認の問題の可能性も含め説明する．	・「わからない」は避ける． ・「不完全」「異常」という言葉は使わない． ・出生届を急がせることは避ける． ・検査結果を個々に説明することを避ける．特に染色体検査結果のみ説明することはしない． ・社会的性決定に際し，**十分な説明がないまま**「どちらにしますか？」「どちらでもいいですよ」といった言い方は避ける．

～1か月	・性腺・内性器の検索終了.（超音波検査, MRI, 尿道造影, 腹腔鏡, 性腺生検等） ・HCG負荷試験*5 ・原疾患の診断確定（可能な限り） ・合併症の治療（副腎/腎疾患等） ・遺伝子検査	・社会的性は生後1か月までには確定できるよう検査等を進める. ・診療計画の確定 ・心理的サポートの継続・強化と必要に応じて遺伝カウンセリング ・原疾患の治療継続 ・性別判定までは入院継続を考慮	・医療者からの社会的性別の提言と診療計画の説明を行い, 両親を含め検討. 両親の希望を充分汲み取る. ・診療計画については, あらゆる治療の可能性と性自認の問題の可能性も含め説明する.	・社会的性決定に際し, **十分な説明がないまま**「どちらにしますか?」「どちらでもいいですよ」といった言い方は避ける.
～6～12か月	・（必要に応じて）テストステロン療法 ・外陰形成術(第一期) ・（必要に応じて）性腺生検・摘出術	・外科（小児泌尿器科や小児外科）と小児科の連携は密にする. ・心理的サポートの継続・強化と必要に応じて遺伝カウンセリング ・原疾患の治療継続 ・産婦人科の意見を聞く.	・長期的診療計画の説明 ・予後の説明（不確定なことは「不確定である」ときちんと説明するが, 希望的側面も話せるとよい. 二次性徴, 性交, 妊孕性についても可能なかぎり説明） ・（必要に応じ）産婦人科医を紹介	
～1.5歳	・外陰形成術 ・（必要に応じて）性腺生検・摘出術	・性自認成立までに終了しておいた方が望ましい泌尿器科処置について確認		

*1 早産児への対応：早産児では1）外性器の発達が未熟であり, 精巣下降が生理的に不十分な場合があることや陰茎長の基準値がないこと, 2）一般状態が不良で, 浮腫などにより診察所見が充分得られなかったり, 脂肪組織が少ないために陰核を肥大と過大評価してしまうことがある, 3）経験豊富な医師による診察の機会が作れない場合があることから, 早期性別判定がしばしば困難となる. 経時的に詳細な観察を要する. 判定に時間がかかることを伝え, 拙速な判断はしないようにするが, 生命予後不良な場合は中途での判断もやむを得ない. この場合, 戸籍上の性変更が可能であることを伝える.

*2 検査項目・検査の手順→表1・図1参照

*3 社会的性決定は複数科の意見を元に判断すること. 集学的チームがあることが望ましい.

*4 泌尿器科・内科治療の実際→表2参照

*5 HCGテスト：精巣機能（テストステロン分泌能）検索が必要な場合に行う.
生後1週以降　2か月くらいまでに行う.
測定項目：テストステロン, DHT（保険未収載）, アンドロステンジオン（保険未収載）